Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition Saori MishimaYoichi NaitoEishi Baba Special Article Open access 20 August 2023 Pages: 1237 - 1258
Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022 Satoru MutoTakeshi MatsubaraMotoko Yanagita Special Article 29 June 2023 Pages: 1259 - 1297
Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022 Hiroyuki NishiyamaTakamitsu InoueThe committee of Clinical practice guidelines for the management of kidney disease during anticancer drug therapy 2022 Special Article 12 August 2023 Pages: 1298 - 1314
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022 Yuichi AndoHiroyuki Nishiyamathe Committee of Clinical Practice Guidelines for the Management of Kidney Disease During Anticancer Drug Therapy 2022 Special Article 16 July 2023 Pages: 1315 - 1332
Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022 Kenji IshikuraKenji OmaeMotoko Yanagita Special Article 07 July 2023 Pages: 1333 - 1342
Acid suppressants reduce the therapeutic effect of immune checkpoint inhibitors and increase the risk of acute kidney injury: a meta-analysis Keisuke OkamotoYoshitaka SaitoMitsuru Sugawara Original Article 08 July 2023 Pages: 1343 - 1353
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1 Makoto NishioYuichiro OheHideaki Mizutani Original Article Open access 07 August 2023 Pages: 1354 - 1368
Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1 Makoto NishioYuichiro OheHideaki Mizutani Correction Open access 09 September 2023 Pages: 1369 - 1370
Clinical significance of intraperitoneal paclitaxel combined with systemic chemotherapy for gastric cancer with peritoneal metastasis Taiki NakashimaTakaaki ArigamiTakao Ohtsuka Original Article 11 July 2023 Pages: 1371 - 1377
Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study Naohisa YoshidaYoshiaki KuriuEigo Otsuji Original Article 14 August 2023 Pages: 1378 - 1387
Clinical significance of metastatic tumor deposit foci in rectal cancer in the lateral pelvic lymph node area Daisuke YamaiYoshifumi ShimadaToshifumi Wakai Original Article 22 July 2023 Pages: 1388 - 1397
Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study Hiroyuki NishiyamaToyonori TsuzukiOsamu Ogawa Original Article Open access 27 July 2023 Pages: 1398 - 1410
Ovarian serous borderline tumors with recurrent or extraovarian lesions: a Japanese, retrospective, multi-institutional, population-based study Tsukasa BabaMasafumi KoshiyamaNobuo Yaegashi Original Article 01 August 2023 Pages: 1411 - 1420
Retrospective study of the efficacy and safety of docetaxel/carboplatin combination therapy as postoperative adjuvant chemotherapy for nonsquamous cell carcinoma of the cervix Ryo KoikeMayu YunokawaAkihiko Sekizawa Original Article 16 August 2023 Pages: 1421 - 1430
